• ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 LIVE!™
Insights
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

First diagnostic test for canine IBD now available

August 14, 2020
dvm360 Staff
dvm360, dvm360 August 2020, Volume 51, Issue 8

Antech’s novel blood test allows veterinarians to rule in or rule out IBD early and with confidence in dogs suffering from associated clinical signs.

Antech Diagnostics (part of Mars Veterinary Health), has announced the availability of its Canine CE-IBD assay, the first blood test for canine inflammatory bowel disease (IBD) (also known as chronic enteropathy, or CE).

Identifying IBD in dogs is traditionally invasive, time-consuming, and costly, but this new blood test allows for a rapid result of “consistent with CE/IBD" or "not consistent with CE/IBD,” according to a company release. It works by incorporating data from three biomarkers—for gliadin sensitivity (similar to gluten sensitivity), bacterial proliferation (Escherichia coli), and intestinal inflammation—to determine possible causes of a dog’s gastrointestinal (GI) signs.

The use of biomarkers, according to a recently published supporting study,1 helps veterinarians determine whether IBD is present, reinforce the need for additional diagnostics, develop more individualized treatment plans, and possibly monitor therapeutic response.

“The opportunity to rule in or rule out IBD early, identify possible causes and use evidence-based medicine to help pet owners understand care recommendations—all quickly and cost-effectively—allow us to treat a dog who is suffering faster,” said Jennifer Ogeer, BSc, DVM, MSc, MBA, MA, vice president of Medical Affairs & Commercial Marketing at Antech, in the release. “We can inspire confidence in a worried pet owner and gain ongoing commitment to our care recommendations, ultimately supporting a dogs rapid return to health.”

The Canine CE-IBD assay can be used when a dog has been experiencing GI signs for a minimum of 3 to 7 days, although results are more accurate when signs persist for at least 3 weeks. The test is currently available to US veterinarians, with availability in Canada following the end of COVID-19–related travel restrictions.

Learn more about this new blood test here.

Reference

1. Estruch, JJ, Barken, D, Bennett, N, et al. Evaluation of novel serological markers and autoantibodies in dogs with inflammatory bowel disease. J Vet Intern Med. 2020;34:1177 1186. doi: 10.1111/jvim.15761

download issueDownload Issue: dvm360 August 2020

Related Content:

MedicalProductsGastroenterologyAssociatesTechniciansdvm360 August 2020
Targeted injectable therapy for canine elbow osteoarthritis
Targeted injectable therapy for canine elbow osteoarthritis
Entrepreneurship: inventing the 5-second Doppler placement solution
Entrepreneurship: inventing the 5-second Doppler placement solution
Tailored Pet adds new supplements and treats for its summer product line
Tailored Pet adds new supplements and treats for its summer product line

Latest News

Shepherd Veterinary Software debuts new pet portal

Why team building makes all the difference in your practice and how to do it right

Virginia veterinarian sentenced for opioid theft

Targeted injectable therapy for canine elbow osteoarthritis

View More Latest News